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BACKGROUND. Cancers can escape immune recognition by means of evading class I major
histocompatibility complex (MHC) -mediated recognition by cytotoxic T lymphocytes. How-
ever, immunization strategies targeting defined tumor-associated antigens have not been
extensively characterized in murine prostate cancer models. Therefore, we evaluated antigen-
specific, antitumor immunity after antigen-encoding vaccinia immunization against mouse
prostate cancer cells expressing a model tumor-associated antigen (b-galactosidase) and
exhibiting partially deficient class I MHC.
METHODS AND RESULTS. Low class I MHC expression in b-galactosidase–expressing
D7RM-1 prostate cancer cells was shown by fluorescence activated cell sorting, and deficient
class I MHC-mediated antigen presentation was shown in resistance of D7RM-1 to cytolysis
by b-galactosidase–specific cytotoxic T lymphocytes (CTL). Despite partially deficient class I
MHC presenting function, immunization with vaccinia encoding b-galactosidase conferred
antigen-specific protection against D7RM-1 cancer. Antigen-specific immunity was recapitu-
lated in b2m knockout mice (with deficient class I MHC and CTL function), confirming that
class I MHC antigen presentation was not required for immunity against tumor partially
deficient in class I MHC. Conversely, antigen-specific antitumor immunity was abrogated in
Abb knockout mice (with deficient class II MHC and helper T cell function), demonstrating
a requirement for functional class II MHC. Resistant tumors from the otherwise effectively
immunized b2m knockout mice (among which tumor progression had been reduced or
delayed) showed reduced target antigen expression, corroborating antigen-specificity (and
showing an alternative immune escape mechanism), whereas antigen expression (like tumor
growth) was unaffected among Abb knockout mice.
CONCLUSION. Our results demonstrate that class I MHC-restricted antigen presentation
and CTL activity is neither necessary nor sufficient for antigen-encoding vaccinia immuniza-
tion to induce protective immunity against class I MHC-low tumors, whereas host class II
MHC-mediated antigen presentation facilitates antigen-specific immunity against prostate
cancer in vivo. Reduced expression of the target antigen developed rapidly in vivo as an
immune escapemechanism for such cancers. Prostate 53: 183–191, 2002. # 2002Wiley-Liss, Inc.
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INTRODUCTION
One mechanism whereby tumor cells escape
immune recognition is by evading class I major
histocompatibility complex (MHC) -mediated tumor
recognition by cytotoxic T lymphocytes (CTL) [1–3].
Prostate cancer specifically has been implicated as
exhibiting class I MHC antigen processing deficiencies
in phenotypic and functional analyses, and reduced
class I MHC expression in prostate cancer has been
found to be associated with advanced stage and grade
of such cancers [4–6]. Other human cancers have
shown similar deficiencies in class I MHC antigen
processing and presentation [1,2]. Preclinical in vivo
studies evaluating immune responses against class I
MHC-deficient cancers, however, have been rare and
have been limited to assessing immune responses
of tumor cell vaccines against unidentified tumor-
associated antigens (TAA) [3,7,8]. Moreover, animal
models previously used to evaluate immune respon-
ses, after immunization against specific tumor anti-
gens, have typically exhibited robust class I MHC
expression and consequent reliance on class I MHC-
directed, cytotoxic T lymphocytes (CTL). In contrast,
the effect of TAA-specific immunization has not been
extensively characterized in prostate cancer models
not requiring interaction between TAA-specific CTL
and class I MHC.
Therefore, we sought to determine whether TAA-
specific immunity could be induced in a setting of
prostate cancer with partially deficient class I MHC
function in the target tumor. Due to the growing
interest in the clinical development of recombinant
poxviruses as TAA-specific vaccines [9,10], we select-
ed vaccinia as the TAA delivery vehicle for these
studies. Among various cancers, prostate cancer re-
presents a relevant setting in which micrometastatic,
preclinical models relate to clinical stages of prostate
cancer in which microscopic cancer burden can serve
as a substrate for clinical vaccine trials. Therefore, a
syngeneic mouse model of prostate cancer (which
we found to exhibit partially deficient class I MHC
function) was used as the target for evaluating anti-
tumor effects of TAA-specific immunization [11].
Because no specific native prostate cancer tumor
antigen has been isolated from transplantable murine
prostate cancer cells, we introduced b-gal to serve as
a model TAA for these studies; prior studies have
shown the utility of b-gal as a target TAA model in
murine systems. Through experiments using RM-1
cells in T cell competent and in CD8 and CD4 knock-
out mice, we show that TAA-specific immunization
with recombinant vaccinia can induce protective
antitumor immunity, despite deficient interaction
between host CTL and tumor class I MHC and that




All cell lines were maintained in Dulbecco’s
modified Eagle media (Life Technologies, Inc., Grand
Island, NY) supplemented with 100 U of penicillin per
ml, 100 mg of streptomycin per ml, and 10% heat-
inactivated fetal bovine serum (Life Technologies,
Inc.) at 378C in a 5% CO2 incubator unless it is
indicated otherwise. Mouse T cell lymphoma lines EL4
(H-2b) and E22 (H-2b) and colon carcinoma cell line
CT26.CL25 (H-2d) have been described previously
[12]. E22 and CT26.CL25 cells express b-gal and are
maintained in 400 mg/ml effective concentration of
G418 media. RM-1 (provided by Dr. T. Thompson,
Baylor College of Medicine) [11] and D7RM-1 cell lines
are prostate cancer cell lines from C57BL/6 mice.
D7RM-1 is a cell line derived from a single cell clone
stably expressing b-gal and was generated by trans-
ducing RM-1 cells with an amphotropic retroviral
vector encoding b-gal as follows: Amphotropic super-
natant transmitting LacZ-expressing retroviral vector
was generated by calcium phosphate transfection of
Phoenix A cells (provided by Dr. G. Nolan, Stanford
University) by using ProFection Mammalian Transfec-
tion System (Promega, Madison, WI). The complete
transfection solution was added onto Phoenix A cells,
which were then incubated at 378C for 8 to 10 hr,
after which cell culture medium was exchanged. Viral
supernatant was collected from producer cell culture
supernatant of days 2–5 filtered through a 0.45-mM
filter to remove Phoenix A cells. Protamine sulfate
(5 mg/ml) (Sigma, St. Louis, MO) was added to the
viral supernatant, which was immediately placed on
105 RM-1 tumor cells that had been plated into each
well on a six-well plate 1 day previously. Limiting
dilution was performed to generate the single-tumor-
cell clones, including D7RM-1. LacZ expression by
D7RM-1was measured at 72 hr by X-gal assay, for
which cells were fixed in phosphate buffered saline
(PBS) with 0.5% glutaraldehyde for 10 min followed
by resuspension in complete staining solution (2 mg/
ml X-gal, 10 mM potassium ferricyanide, 10 mM
potassium ferrocyanide, 4 mM MgCl2), followed by
incubated at 378C in the dark for 2–4 hr, after which
detection of blue cells at 100 microscopy confirmed
the presence of b-gal.
FluorescenceActivatedCell SortingAnalysis
RM-1 mouse prostate cancer cells, LacZ transduced
D7RM-1 cells, or controls were washed twice with
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fluorescence activated cell sorting (FACS) buffer (PBS
supplemented with 0.1% bovine serum albumin and
0.1% sodium azide), and one million cells were in-
cubated with 0.5 mg of fluorescein isothiocyanate
(FITC) -conjugated antibody specific for class I MHC
(Accurate Chemical & Scientific Corporation, San
Diego, CA) or isotype control antibody in a final
volume of 50 ml at 48C for 30–40 min. Cells labeled
with isotype-control antibody were used to determine
background fluorescence, and total of 10,000 viable
cells were analyzed per sample in a FACScan flow
microfluorometer (Becton Dickinson, Sunnyvale, CA).
Vaccinia
Recombinant vaccinia viruses rVV-b-gal and V69
were produced as previously described [13,14]; for
rVV-b-gal, LacZ gene was driven by the synthetic
early/late promoter (pSE/L) [11]. Purified virus was
prepared and titered as described by Earl and Moss
[15].
Animals
All experiments were approved by the University
of Michigan Committee on Use and Care of Animals
and were conducted in accordance with National
Institutes of Health guidelines. Six- to 8-week-old male
C57BL/6 mice were purchased from Harlan Sprague-
Dawley, Inc. (Indianapolis, IN). b2m and A
bb knock-
out mice in the C57BL/6 background were purchased
from TACONIC, Inc. (Germantown, NY); these strains
have been demonstrated to be deficient in the ex-
pression of functional class I and class II MHC mole-
cules, respectively [16,17]. Previous studies have
shown that CD8þ cells and CD4þ cells are essentially
undetectable in the periphery of b2m knockout (CD8þ
cells at limits of detection) and Abb knockout mice
(CD4þ cells at limits of detection), respectively, com-
pared with the normal mice [17,18]. For experiments
evaluating protection against tumor challenge after
immunization, C57BL/6, b2m knockout, and A
bb
knockout mice were immunized by intravenous tail
vein injection with 107 plague-forming units (pfu) per
mouse of rVV-b-gal or V69 (control vaccinia). Three
weeks later, 105 b-gal expressing D7RM-1 tumor cells
were injected subcutaneously in the right flank.
Animals were monitored at least three times weekly
for the appearance of measurable tumors, tumor pro-
gression, and survival by an individual blinded to the
immunization status of the animals. Mice were fol-
lowed up until death from cancer or were killed when
the tumors interfered with the animal’s well-being,
as shown by ungroomed fur, slow movement, or
cachexia. Death was confirmed to be tumor-related by
means of postmortem examination.
Generation of CTL andAssayof CTL-Mediated
TumorCell Cytolysis
Mice were immunized with 107 pfu per mouse
of rVV-b-gal or control vaccinia (V69) by means of
an intravenous tail vein injection. Splenocytes were
harvested 3 weeks later and were stimulated in vitro
with 1 mg/ml of b-gal peptide (DAPIYTNV) [19] and
10 U/ml of recombinant IL-2 for 1 week to generate b-
gal–specific CD8 CTL. A 6-hr 51Cr-release assay was
used to assess the cytotoxic activity of these CTL.
Briefly, 106 target cells were labeled with 51Cr for 1–
2 hr. Labeled target cells (E22, EL4, CT26.CL25, RM-1,
and D7RM-1) were incubated with various numbers of
effector cells (effector to target [E:T]¼ 100, 33, 11, and
3.7) at 378C for 6 hr. An automated gamma counter
(Skatron Instruments, Inc., Sterling, VA) was used to
measure chromium release. Percentage specific lysis
was calculated from triplicate samples as follows:
([experimental counts per minute {cpm}spontaneous
cpm]/[maximal cpm spontaneous cpm]) 100. Data
included in this report represent assays in which
spontaneous release of labeled target cells was less
than 20% ofmaximal release and standard deviation of
triplicate values was less than 15%.
QuantitativeAssayofb-gal Expression
inTumorTissue
Tumors were harvested from killed mice, rinsed,
homogenized, and resuspended in protein lysis buffer
(5 mM Tris, 120 mM NaCl, 15% IGEPAL, Sigma) with
proteinase inhibitors phenylmethyl sulphonyl fluor-
ide, leupeptin, and aprotinin (Boehringer Mannheim,
Indianapolis, IN). The tumor lysate suspension was
then centrifuged at 14,000g for 15 min. Protein con-
centration in the supernatant was determined by using
the Bio-Rad protein assay kit (Bio-Rad Laboratories,
Hercules, CA). Triplicate samples containing 90 mg of
total protein each in 50 ml were added to individual
wells in 96-well plates with 100 ml of buffer (2 mM
MgCl2, 0.1 mM b-mercapthoethanol, 0.1 M sodium
phosphate, pH 7.5) and 50 ml of the substrate o-
nitrophenyl-galactopyranoside (ONPG; 4 mg/ml) and
incubated at 378C before the reaction was stopped
by the addition of 100 ml of 1 M Na2CO3. A standard
curve was generated with known amounts of b-gal.
The colorimetric reaction of the samples was read at
405 nm by using a MRX automated microplate reader
(Dynatech Lab, Chantilly, VA).
Statistical Analysis
Differences in tumor-free and overall survival
between groups of immunized mice were evaluated
for significance by using the log rank test. Differences
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in b-gal expression as measured by ONPG assay were
evaluated for significance by using the t-test. Signifi-
cance was set at P¼ 0.05 for all comparisons and
analyses were performed by using STATISTICA soft-
ware (Tulsa, OK).
RESULTS
Class IMHCExpression and Function in the
Mouse Prostate CancerCell LineD7RM-1
To generate amouse prostate cancer cell line expres-
sing b-gal as model tumor-associated antigen (TAA),
themouse prostate cancer cell line RM-1 was transduc-
ed with a retroviral vector encoding b-gal (Materials
and Methods section), and limiting dilution was used
to isolate b-gal expressing clones (D7RM-1) after scre-
ening for b-gal expression by X-gal assay. The cell
surface expression of class I MHC by D7RM-1 cells
was evaluated by FACS analysis by using a FITC-
conjugated mouse class I MHC framework antibody
(Fig. 1). A T-lymphoma cell line, EL4, and its b-gal
expressing subclone, E22, were used as positive con-
trols for class I MHC expression in these analyses.
Like the parental RM-1 cells (Fig. 1A), D7RM-1 cells
are deficient in class I MHC expression (Fig. 1B). To
determine possible effects of b-gal expression on the
tumorigenicity of RM-1 cells, D7RM-1 cells (expres-
sing b-gal) and untransduced RM-1 were injected
subcutaneously in groups of C57BL/6 mice. The mice
were followed at least three times weekly for the ap-
pearance of measurable tumors, tumor progression,
and survival. No significant difference in tumor
growth and progression in vivo was found between
D7RM-1 and its parental cell line, RM-1 (data not
shown).
We next sought to evaluate the ability of D7RM-1
prostate cancer cells to present the model TAA (b-gal)
to CTL with specificity against this model TAA. Such
class I MHC-restricted antigen presentation was eva-
luated, by measuring the susceptibility of D7RM-1
prostate cancer cells to cytolysis by b-gal–specific CTL
(induced by means of recombinant vaccinia immuni-
zation). CTL were derived by immunizing C57BL/6
mice with vaccinia control (V69, Fig. 2A) or rVV-b-gal
(Fig. 2B). Specificity of rVV-b-gal immunization-
derived CTL for the model TAA was confirmed by
b-gal–specific CTL-mediated cytolysis of b-gal expres-
sing E22 (H-2b) target cells that have abundant class I
MHC, whereas b-gal negative, syngeneic EL-4 cells
were not lysed (Fig. 2B). These b-gal–specific CTL
(from C57BL/6 mice with H-2b class I MHC) did not
lyse b-gal expressing, CT26.CL25 targets (from Balb-c
mice with H-2d class I MHC), indicating that the
observed b-gal–specific CTL activity was class I MHC
restricted. In contrast, neither b-gal–negative RM-1
cells nor b-gal–positive D7RM-1 cells were lysed by
Fig. 1. Class I major histocompatibility complex (MHC) expres-
sion inD7RM-1and RM-1prostate cancer cell lines asmeasuredby
flowcytometry.RM-1 (A) andD7RM-1 (B) cellswere stainedwith a
fluorescein isothiocyanate^conjugated class I MHC-specific anti-
body.The dashedlinesrepresent samples stainedwith isotype con-
trol antibodies.EL4 cell line (C) and the derivative b-gal expressing
E22 cell line (D) were stained as controls showing abundant class I
MHCexpression.
Fig. 2. D7RM-1prostate cancer cells are functionallydeficient in
antigen presentation to class I major histocompatibility complex
(MHC)-restricted cytotoxic T lymphocytes (CTL). C57BL/6 mice
(H-2b) were immunizedwith107 plaque forming units control vec-
tor (V69,A) or b-gal^encoding recombinant vaccinia virus (rVV-b-
gal, B). Splenocytes were prepared 3 weeks later and stimulated
with b-gal peptide in vitro for a week to generate b-gal^specific
CTL.The ability of target tumor cells to present antigen in a class I
MHC-restricted manner to these b-gal^specific CTL was evalu-
atedbymeans of chromiumrelease cytotoxicity assay as described
in the Materials and Methods section.Tumor target cells included
those with b-gal (E22, D7RM-1) or without b-gal (EL4, RM-1). b-
gal^expressing CT26.CL25 cell line (H-2d) was used as a control
for class I MHC-restricted antigen presentation. E:T, effector to
target.
186 Neeleyet al.
b-gal–specific CTL induced by rVV-b-gal (Fig. 2B),
indicating that D7RM-1 failed to present the model
TAA (b-gal), by means of class I-MHC, to CTL specific
for the model TAA.
InVivo Eff|cacyof Recombinant Vaccinia
Immunization as PreventionAgainst RM-1
ProstateCancerGrowth and Progression
To characterize the in vivo antitumor efficacy of
TAA-specific recombinant vaccinia immunization
against growth and progression of class I MHC-
deficient tumors, C57BL/6 mice were next immunized
with rVV-b-gal followed by subcutaneous challenge
of b-gal TAA–expressing, D7RM-1 tumor cells. Al-
though 100% of the control vaccinia V69-immunized
mice developed D7RM-1 tumor early and died within
1 month of tumor challenge, approximately 40% of the
mice immunized with rVV-b-gal were tumor-free and
alive 3 months or longer after tumor challenge (Fig. 3;
P¼ 0.002). Therefore, TAA-specific immunization, with
recombinant vaccinia virus, induced TAA-specific im-
munity against class I MHC-deficient D7RM1 prostate
cancer cells in vivo (Fig. 3), despite the demonstrated
deficiency of these tumor cells in class I MHC-mediat-
ed antigen presentation (Fig. 2).
Role of Class IMHCandClass IIMHCFunction in the
Prostate CancerHostAnimal
To further ascertain that antigen presentation to
class I MHC-restricted CTL was not involved (in
the observed protection against D7RM-1 tumor after
rVV-b-gal immunization), immunization and D7RM-1
challenge experiments were repeated in class I MHC
knockout b2m-/- mice. As expected, rVV-b-gal immu-
nization of b2m-/- mice failed to induce b-gal–specific
CTL (Fig. 4). However, despite the absence of b-gal–
specific CTL, b2m-/- mice immunized with rVV-b-gal
were protected against D7RM-1 tumor growth in an
antigen-specific manner (Fig. 5D), demonstrating that
TAA-specific protection can be conferred, indepen-
dent of class I MHC-restricted antigen presentation by
either tumor or host in vivo.
The requirement for competent class II MHC
function for induction of effective, TAA-specific
immunity against class I MHC-deficient D7RM1
tumor was next assessed by means of vaccinia
immunization of class II MHC knockout (Abb-/-)
Fig. 3. Recombinant vaccinia encoding a model TAA (b-gal)
inducesTAA-specific immunityinvivo againstRM-1prostate cancer
cells.C57BL/6micewere immunizedwith107 plaque formingunits/
mouse of rVV-b-gal (filled symbols) or control vector V69 (open
symbols).Threeweeks later, immunizedmicewere challengedwith
105D7RM-1tumorcells subcutaneously and followedup for tumor-
related death (n¼10 mice per therapy group; P¼ 0.002). Similar
findings confirmed in three separate experiments.
Fig. 4. Immunization with recombinant vaccinia virus induces
tumor antigen-specific cytotoxicT lymphocytes (CTL) activity in
Abb knockout (class II major histocompatibility complex [MHC]
nonfunctional) mice but not in b2-microglobulin (b2-m) knock-
out (class I MHC nonfunctional) mice. Abb knockout and b2-
microglobulin knockout mice were immunized with 107 plaque
forming units V69 (A,C) or rVV-b-gal (B,D). To detect elicited,
b-gal^specific CTL, splenocytes were harvested 3 weeks after
immunization, stimulated with b-gal peptide, and evaluated by
chromium release CTL assay as described in the Materials and
Methods section. Targets for distinguishing b-gal^specific class I
MHC-restricted CTL activity included tumor targets with (E22,
D7RM-1) or without (EL4, RM-1) the expression of b-gal. b-gal^
expressing CT26.CL25 cell line (H-2d) was used as a control for
MHCrestriction.
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mice. Of interest, the ability to induce b-gal–specific
class I MHC-restricted CTL activity by rVV-b-gal
immunization was present in class II MHC knockout
mice (Fig. 4). However, despite induction of class I
MHC restricted b-gal–specific CTL activity, immuni-
zation with recombinant vaccinia encoding the target
tumor antigen (rVV-b-gal) did not induce effective,
antigen-specific, immune protection against tumor
growth and progression in class II MHC knockout
mice (Fig. 5A). Abrogation of effective immunity was
also noted in interferon-gamma (IFN-g) knockout mice
(Fig. 5C), suggesting that the class II MHC-mediated
response required for effective immunity against class
I MHC-deficient tumors may occur by means of Th1
pathways. These observations suggest that class I
MHC-restricted TAA recognition is neither necessary,
nor sufficient, for the induction of effective, TAA-
specific immunity against class I MHC-deficient
cancer cells.
We next sought to determine whether TAA expres-
sion (among immunity-resistant D7RM1 tumors)
corroborated the presence of effective, TAA-specific
immunity in class I MHC knockout mice compared
with deficient antigen-specific immunity in class II
MHC knockout mice. We hypothesized that, if potent
TAA-specific immunity is present, then immunity-
resistant tumors could be expected to show reduced
levels of TAA expression compared with tumors from
control mice. To test this hypothesis, model TAA
(b-gal) immunization-resistant tumors from class I
knockout and class II knockout mice were evaluated
for levels of b-gal expression by ONPG assay. Tumors
that eventually grew in class I MHC knockout mice
immunized with rVV-b-gal showed reduced b-gal
expression compared with tumors from control mice,
whereas b-gal expression in resistant outgrowing
tumors from class II MHC knockout mice immunized
with rVV-b-gal were unaffected (Fig. 5D). These find-
ings corroborate that TAA-specific immunization can
specifically eliminate TAA-expressing tumors in the
absence of class I MHC-mediated antigen presenta-
tion but that reduced TAA expression represents a
mechanism for possible escape, by such tumors, from
immune recognition.
DISCUSSION
We have demonstrated the ability of recombinant
vaccinia virus encoding a model tumor-associated
antigen (TAA) to induce effective, TAA-specific im-
munity in vivo that is independent of interaction
between CTL and class I MHC presenting the target
TAA. Through in vivo studies using knockout mice
(lacking class I MHC, or class II MHC, or IFN-g), we
found that class I MHC-restricted TAA recognition is
neither sufficient, nor necessary, for the induction of
such TAA-specific immunity against RM-1 prostate
cancer cells. In contrast, both class II MHC-mediated T
cell help and IFN-g were required. Limitations of this
study include use of a single cell line with a model
TAA that is not a native prostatic TAA.
Our findings complement and extend the priorwork
of Smyth et al. and Griffith et al., who studied non-
specific, natural killer (NK) cell-mediated immunity
by using the RM-1 prostate cancer model [7,8,20,21].
Smyth et al. evaluated immunity against RM-1 cells
and class I MHC-deficient lymphoma tumor lines, but
evaluated neither class I MHC-mediated CTL nor class
II MHC-mediated CD4 helper T cell activity in studies
that focused largely on NK responses against uni-
dentified antigens [7,8,21]. Griffith et al. similarly
focused on NK-mediated responses in the setting of
Fig. 5. Class IImajor histocompatibilitycomplex (MHC) (butnot
class IMHC) -restricted antigen presentation is required for effec-
tive tumor antigen-specific immunization and consequent reduced
TAA levels in immunization-resistant tumors.Class IIMHC knock-
out mice (A), class I MHC knockout mice (B), and interferon-g
knockoutmice (C) were immunized with107 plaque forming units
of either V69 (open symbols) or rVV-b-gal (filled symbols). Three
weeks after immunization, mice were challenged by 105 D7RM-1
tumor subcutaneously and followed for tumor-related death. Sig-
nificantprotection invivo against tumor challenge after immuniza-
tionwas observedonly inclass IMHCknockoutmice (B;P¼ 0.007),
whereas antigen-specific protection against tumor challenge was
abrogated (not significant) in class II MHC as well as interferon-g
knockoutmice (A,C).D:To determinewhether rVV-b-gal immuni-
zation led to robust b-gal^specific immune response in vivo,
expression of b-gal in refractory, progressive (immunization-resis-
tant) tumors was evaluated by o-nitrophenyl-galactopyranoside
(ONPG) assay. b-gal expression in tumors fromclass IMHCknock-
out (KO) mice immunized with rVV-b-gal were significantly lower
than in controlmice (P¼ 0.03), whereas b-gal levels in class IIMHC
knockoutmice were unaffected by rVV-b-gal immunization (b-gal
levels in tumor tissue fromrVV-b-gal immunizedmice are shownas
a percentage of b-gal levels found in tumor tissue fromV69-immu-
nized controlmice).
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unidentified TAA, and showed that neither CD8 CTL
nor class II MHC-mediated CD4 T helper function
were required for such nonspecific, NK-mediated
antitumor activity [20]. Neither Smyth et al. nor
Griffith et al. reported mechanisms of resistance that
were associated with tumors refractory to immu-
notherapy. The studies described herein complement
these prior works by focusing on antigen-specific
immune responses, such as would be relevant to TAA-
specific tumor vaccines and immunotherapy. Our
findings indicate that mechanisms of TAA-specific
immunity may differ from those previously reported
as required for NK-mediated immunity lacking a
defined TAA target. Our use of a model expressing a
defined TAA also showed the potential for loss of TAA
expression in vivo to provide a resistance mechanism
against TAA-specific immunotherapy. Such TAA-loss
mechanisms of immune evasion have not been ex-
tensively characterized previously by in vivo models.
There is published controversy regarding the ade-
quacy of class I MHC expression in RM-1 cells: Smyth
et al. reported absent class I MHCwith no change after
stimulation with IFN-g in vitro, whereas Griffith et al.
reported low but detectable class I MHC and increas-
ed expression after stimulation with IFN-g in vitro
[7,8,20]. Our observations were consistent, in part,
with both prior reports: like Smyth et al., we could
detect no class I MHC by flow cytometry in the
absence of IFN-g stimulation in vitro (Fig. 1); however,
consistent with the findings of Griffith et al., we
observed that class I MHC could be detected by flow
cytometry after supra-physiological IFN-g stimulation
in vitro (data not shown). We extended beyond the
prior observations of Griffith et al. and of Smyth et al.
by showing that the low class I MHC expression by
RM-1 is associated with defective antigen presenta-
tion to antigen-specific CTL (in the absence of IFN-g)
as measured by chromium release assay (Fig. 2). Our
findings suggest that the conflicting prior reports
regarding class I MHC in RM-1 cells can be reconciled
by concluding that RM-1 cells have variably deficient
class I MHC function that can be augmented by IFN-g
under some conditions: In sum, class I MHC function
in RM-1 cells can show variable deficiency but is not
completely absent.
Irrespective of the severity of class I MHC function
deficiency in RM-1 prostate cancer cells, studies with
class I MHC knockout mice showed that mechanisms
requiring interaction between CTL and class I MHC
are not necessary for effective, antigen-specific anti-
tumor immunity in vivo (Fig. 5B). Lack of the ability to
elicit b-gal–specific CTL from class I MHC knockout
mice (after rVV-b-gal immunization) demonstrated
that retaining TAA-specific antitumor immunity in
class I MHC knockout mice was not due to persistent
functional CTL in the class I MHC knockout mice: we
were unable to detect any significant, antigen-specific,
CTL activity either from splenocytes (Fig. 4) or from
tumors (data not shown) of such mice. This finding
contrasts with a prior report which showed that CTL
specific for allogeneic class I MHC could be elicited
from allogeneic tumors in these class I MHC knockout
mice [22]. Our findings suggest that emergence of CTL
(despite absent b2-microglobulin) in class I MHC
knockout mice may depend on the model tumor
antigen target and can be absent when allogeneic
MHC is not the tumor antigen. Moreover, we found
that the ability to induce TAA-specific CTL was not
sufficient to eliminate the class I MHC-deficient tumor
in vivo, as demonstrated by the absence of protection
against D7RM-1 growth in class II MHC knockout
mice, despite b-gal–specific CTL induction (Figs. 4, 5).
In our model for inducing a nonself, TAA-specific
immune response by recombinant poxvirus immu-
nization, CTL responses restricted by class I MHC-
mediated antigen presentation were neither required
nor sufficient to generate effective, antigen-specific
antitumor immunity against class I MHC-deficient
tumor.
In contrast, class II MHC function was required (in
the tumor-bearing host) for effective TAA-specific
immunization against class I MHC-deficient D7RM-1
tumor, as demonstrated by TAA-specific immunity
being abrogated in Abb knockout mice. The class II
MHC-mediated function can be ascribed to host cells
(rather than the target tumor) because, as in most
tumor cells, D7RM-1 cells do not express class II MHC
molecules (data not shown). Mechanisms whereby
class II MHC-mediated TAA processing and presen-
tation by host antigen-presenting cells can induce
effective TAA-specific immunity include Th1 cell-
mediated activation of CTL, natural killer (NK) cells,
or macrophages [3,23–27]. The ability of CTL to confer
TAA specificity in the effector phase of TAA-specific
responses is well characterized; however, our data
suggest that CTL were not the principal effector cells
against class I MHC-deficient tumor. NK cells and
macrophages may be involved in killing of the b-gal
expressing, class I MHC-deficient tumor in a non–
tumor antigen-specific manner. However, the reduced
TAA expression we observed in tumors refractory to
TAA immunization (Fig. 5D) corroborated that elim-
ination of class I MHC-deficient tumor was associated
with antigen specificity in vivo.
The mechanism of antigen-specificity in the effector
component of immune responsiveness against class I
MHC-deficient tumor, such as observed herein, re-
mains elusive. In our model, the target tumor antigen
was cytosolic, rendering it unlikely that antigen-
specific antibodies were pivotal; however, a possible
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role for humoral effectors, such as tumor antigen-
specific antibody that others have found to contribute
in class I MHC abundant models, has not been ex-
cluded. [28] Other possible mechanisms include
models whereby Th1 cells promote antigen-specific
tumor cell death consequent to their interaction with
antigen-presenting cells that present tumor antigen
in the vicinity of class I deficient, tumor antigen-
expressing tumor cells. Examples of the latter are
Fas-mediated, antigen-restricted cytolysis by CD4þ T
lymphocytes [29,30] or stimulation of NK cells or
macrophages due to antigen-specific secretion of
IFN-g such as by TAA-specific Th1 cells [21,23]. Of
interest, others have also found that immunogenicity
in the mouse prostate reconstitution model (from
which RM-1 cells were derived) has been shown to be
associated with resistance to CTL-mediated lysis [31].
We found that antigen-specific immunity in our class I
MHC-deficient model was abrogated in mice lacking
IFN-g. This observation indirectly implicates Th1 cells
as important for induction of CTL-independent
cellular effectors against class I MHC-deficient tumor
cells. A similar requirement for IFN-g has been shown
previously for tumor models with abundant class I
MHC [23].
Our findings demonstrate that TAA-specific im-
munity against low class I MHC prostate cancers
can be induced by means of immunization with TAA-
encoding vaccinia. Absence of functional class II
MHC in the vaccine recipient resulted in a profound
defect in effective, TAA-specific, immunity induction
by recombinant vaccinia virus against class I MHC-
deficient tumor. The lack of protection (in absence of
effective host class II MHC function) was associated
with unaffected levels of tumor antigen expression in
progressive tumors. Although the effector mechanism
responsible for the elimination of the class I MHC low
tumor remains undefined and under investigation,
the requirement of both a competent class II MHC
pathway and IFN-g suggest that class II MHC-
mediated antigen presentation, and possibly Th1
cells, can serve a pivotal role in vaccinia virus-
induced, antigen-specific protection against class I
MHC-deficient cancers in vivo. These findings sup-
port efforts to develop vaccine and immune therapies
that do not rely exclusively on immune responses
mediated by means of class I MHC antigen presenta-
tion [32,33].
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